Core Insights - The company reported a revenue of 457 million RMB and a gross profit of 197 million RMB for the six months ending June 30, 2025, with R&D costs amounting to 46.046 million RMB [1] - The hematology testing services saw a steady growth in hospital partnerships, adding over 90 new hospital clients in the first half of 2025 [1] - The pediatric hematology segment continued to expand, with 48 new hospital collaborations established during the same period [1] - The NGS testing product for IG/TCR rearrangement technology experienced over 50% sales growth, highlighting the company's core technological advantages [1] - In the neurology sector, the company expanded its testing projects, adding 34 new tests and 44 new collaborating hospitals [1] Innovation and R&D - The company emphasized innovation-driven development, publishing 33 research articles and applying for 67 patents, with 29 granted and 24 copyrights obtained in the first half of 2025 [2] - A total of 56 new R&D testing projects were introduced, including 16 related to molecular biology, 16 to flow cytometry, 7 to cytogenetics, and 6 to pathology [2] - The core product in the immune repertoire, used for minimal residual disease detection in hematological malignancies, expanded to over 160 institutions across 26 provinces, with revenue growth of nearly 30% compared to the same period in 2024 [2] - The company's subsidiary, Kangsheng Beitai, achieved a perfect score in the EuroClonality EQA program, marking a significant step towards internationalization in the field of immune repertoire testing in China [2]